73.45 USD
↗ 0.36 (0.49%)AT CLOSE (11:59 AM EDT)
Nektar Therapeutics
NKTRNASDAQ • USD
73.90
↗ 0.45 (0.61%)
POST MARKET (AS OF 07:37 PM EDT)
Post Market
AS OF 07:37 PM EDT
73.90
↗ 0.45 (0.61%)
Market: CLOSED
NKTR is currently priced at $73.52. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Aug 6, 2026.
Open?$72.66
High?$74.19
Low?$72.41
Prev. Close?$73.09
Volume?403.6K
Avg. Volume?1.1M
VWAP?$73.53
Rel. Volume?0.38x
Bid / Ask
Bid?$60.67 × 100
Ask?$85.50 × 100
Spread?$24.83
Midpoint?$73.09
Valuation & Ratios
Market Cap?2.5B
Shares Out?33.8M
Float?28.9M
Float %?97.4%
P/E Ratio?N/A
P/B Ratio?4.29
EPS?-$4.68
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Themes
Address
455 MISSION BAY BOULEVARD SOUTH
SAN FRANCISCO, CA 94158
Phone: (415) 482-5300
SAN FRANCISCO, CA 94158
Phone: (415) 482-5300
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?15
Momentum?97
Short Sent.?25
Piotroski F-Score?2/9Weak
Altman Z-Score?1.27Distress
Confidence?55%Low
Short InterestSqueeze Risk
Short % of Float?23.59%Squeeze Risk
Short Interest?6.8M
Days to Cover?7.0
Free Float28.9M
Avg Daily Volume978.2K
Settlement Date2026-07-15
Financial Health
Current Ratio?10.21Strong
Quick Ratio?10.21Strong
Cash Ratio?2.59Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?4.29FAIR▾
Peers100
S&P42
P/S?44.39HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-18.7CHEAP▾
S&P97
EV/Sales?41.70HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-27.4%WEAK▾
S&P6
ROA?-20.7%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-203943000
Enterprise Value?$2.3B
Fundamentals ratios updated end of day